Abbonarsi

Extended-spectrum β-lactamase-producing Escherichia coli in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study - 28/11/19

Doi : 10.1016/S1473-3099(19)30273-7 
Michaela J Day, PhD a, Katie L Hopkins, PhD a, David W Wareham, PhD b, Mark A Toleman, PhD c, Nicola Elviss, PhD a, Luke Randall, PhD d, Christopher Teale, MSc d, Paul Cleary, MSc e, Camilla Wiuff, PhD f, *, Michel Doumith, PhD a, †, Matthew J Ellington, PhD a, Neil Woodford, PhD a, David M Livermore, ProfPhD a, g, ⁎
a National Infection Service, Public Health England, London, UK 
b Barts and The London School of Medicine and Dentistry, London, UK 
c School of Medicine, Cardiff University, Cardiff, UK 
d Animal and Plant Health Agency, Addlestone, UK 
e Public Health England, Liverpool, UK 
f Health Protection Scotland, Glasgow, UK 
g University of East Anglia, Norwich, Norfolk, UK 

* Correspondence to: Prof David M Livermore, University of East Anglia, Norwich, Norfolk NR4 7UQ, UK University of East Anglia Norwich Norfolk NR4 7UQ UK

Summary

Background

Extended-spectrum β-lactamase-producing Escherichia coli isolates (ESBL-E coli) cause more than 5000 cases of bacteraemias annually in the UK. The contribution of the food chain to these infections is debated. We aimed to identify the most important reservoirs of ESBL-E coli that colonise and infect humans to identify strategic intervention points.

Methods

Sampling for ESBL-E coli was done between Aug 1, 2013, and Dec 15, 2014. We used selective media to seek ESBL-E coli in routinely submitted samples from human faeces, and prospectively collected samples from sewage, farm slurry, and retail foodstuffs in London, East Anglia, northwest England, Scotland, and Wales. We sequenced recovered isolates and compared these isolates with 293 bloodstream and 83 veterinary surveillance ESBL-E coli isolates from the same regions.

Findings

2157 (11%) of 20 243 human faeces samples contained ESBL-E coli, including 678 (17%) of 3995 in London. ESBL-E coli also were frequent in sewage and retail chicken (104 [65%] of 159 meat samples), but were rare in other meats and absent from plant-based foods (0 of 400 fruit and vegetable samples). Sequence type (ST) 131 dominated among ESBL-E coli from human blood (188 [64%] of 293 isolates), faeces (128 [36%] of 360), and sewage (14 [22%] of 65) with STs 38 and 648 also widespread; CTX-M-15 was the predominant ESBL in these lineages (319 [77%] of 416). By contrast, STs 602, 23, and 117—mostly with CTX-M-1 ESBL—dominated among food and veterinary isolates (68 [31%] of 218), with only two ST131 organisms recovered. ST10 occurred in both animals and humans, being frequent in surveillance bovines (11 [22%] of 51 cattle) and representing 15 (4%) of 360 human faecal isolates (but only three [1%] of 293 from bacteraemias); however, both human and animal ST10 isolates were diverse in serotype.

Interpretation

Most human bacteraemias with ESBL-E coli in the UK involve internationally prevalent human-associated STs, particularly ST131; non-human reservoirs made little contribution to invasive human disease. Any interventions that seek to target food or livestock can affect the numbers of human infections caused by ESBL-E coli; prevention of the spread of resistant lineages among humans is more vital.

Funding

NIHR Policy Research.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2019  The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 19 - N° 12

P. 1325-1335 - dicembre 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017
  • GBD 2017 Non-Typhoidal Salmonella Invasive Disease Collaborators, Jeffrey D. Stanaway, Andrea Parisi, Kaushik Sarkar, Brigette F. Blacker, Robert C Reiner, Simon I. Hay, Molly R Nixon, Christiane Dolecek, Spencer L. James, Ali H Mokdad, Getaneh Abebe, Elham Ahmadian, Fares Alahdab, Birhan Tamene T Alemnew, Vahid Alipour, Fatemeh Allah Bakeshei, Megbaru Debalkie Animut, Fereshteh Ansari, Jalal Arabloo, Ephrem Tsegay Asfaw, Mojtaba Bagherzadeh, Quique Bassat, Yaschilal Muche Muche Belayneh, Félix Carvalho, Ahmad Daryani, Feleke Mekonnen Demeke, Asmamaw Bizuneh Bizuneh Demis, Manisha Dubey, Eyasu Ejeta Duken, Susanna J Dunachie, Aziz Eftekhari, Eduarda Fernandes, Reza Fouladi Fard, Getnet Azeze Gedefaw, Birhanu Geta, Katherine B Gibney, Amir Hasanzadeh, Chi Linh Hoang, Amir Kasaeian, Amir Khater, Zelalem Teklemariam Kidanemariam, Ayenew Molla Lakew, Reza Malekzadeh, Addisu Melese, Desalegn Tadese Mengistu, Tomislav Mestrovic, Bartosz Miazgowski, Karzan Abdulmuhsin Mohammad, Mahdi Mohammadian, Abdollah Mohammadian-Hafshejani, Cuong Tat Nguyen, Long Hoang Nguyen, Son Hoang Nguyen, Yirga Legesse Nirayo, Andrew T Olagunju, Tinuke O Olagunju, Hadi Pourjafar, Mostafa Qorbani, Mohammad Rabiee, Navid Rabiee, Anwar Rafay, Aziz Rezapour, Abdallah M. Samy, Sadaf G. Sepanlou, Masood Ali Shaikh, Mehdi Sharif, Mika Shigematsu, Belay Tessema, Bach Xuan Tran, Irfan Ullah, Ebrahim M Yimer, Zoubida Zaidi, Christopher J L Murray, John A Crump
| Articolo seguente Articolo seguente
  • Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study
  • Carlos Mejia-Chew, Jane A O’Halloran, Margaret A Olsen, Dustin Stwalley, Ryan Kronen, Charlotte Lin, Ana S Salazar, Lindsey Larson, Kevin Hsueh, William G Powderly, Andrej Spec

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.